Solvay Healthcare markets a wide range of products, most of which are the result of Solvay's own pioneering research and development programmes.

Cardiovascular

Solvay Healthcare has a portfolio of 3 cardiology drugs, Teveten and Physiotens (for raised blood pressure) and Omacor (a life saving treatment for heart attack sufferers).

Gastroenterology

Solvay Healthcare Ltd has been heavily involved in the gastroenterology therapy area since the launch of lactulose for the treatment of constipation, in the 1960s. This was followed in 1978 by the launch of Colofac for the treatment of irritable bowel syndrome, and in 1985, by the launch of Creon for patients with cystic fibrosis. In more recent times, Solvay has expanded its gastroenterology portfolio by successfully bringing line extensions of these popular products to the market, including Creon 40000 in 2002. The company continues to focus on gastroenterology, and further product launches are anticipated in the near future.

Influenza

Influvac influenza vaccine is a sub-unit vaccine, which means that it contains only those parts of the influenza virus that are absolutely needed for effective vaccination. The sub-unit Influenza vaccine Influvac has been on the market since the early eighties.

Neuroscience

In January 2005, Solvay Pharmaceuticals acquired Neopharma AB, a company based in Uppsala, Sweden and added Duodopa, an important new therapy for people suffering from advanced Parkinson's Disease, to its product portfolio which will be available in the second quarter of 2006. 

Duodopa is a treatment based on continuous dopaminergic stimulation by means of a formulation of well-known tried and tested substances, levodopa and carbidopa, dispersed as a viscous gel.  Using a specially designed patient-operated portable pump, the drug is continuously delivered via a tube directly into the duodenum. 

Hormone Replacement Therapy (HRT)

Solvay Healthcare has extensive experience in Hormone Replacement Therapy (HRT), for the treatment of menopausal symptoms and second line prevention of osteoporosis.

Solvay Healthcare's HRT products include:

• Femoston - for women who are still experiencing a natural monthly bleed.
• Femoston-conti - for women, 54+, who no longer experience monthly bleeds.

Many other products are long-established market leaders in their fields in the UK and/or worldwide such as Serc for treating certain disorders of balance and Faverin?? for management of mood disorders.